Roche providing multiple testing solutions to the Canadian healthcare system
Roche’s new Elecsys® Anti-SARS-CoV-2 antibody test now available in Canada is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2.
Public Health, hospital and private laboratories are able to run the Elecsys® Anti-SARS-CoV-2 serology test on Roche’s cobas e analyzers, which are already widely available across Canada, and in each province. These fully automated systems can provide Anti-SARS-CoV-2 test results in approximately 18 minutes, with a test throughput of up to 300 tests/hour, depending on the analyzer.
This test is a complement to Roche’s existing molecular cobas® SARS-CoV-2 test, authorized under Health Canada’s Interim Order, which detects the novel coronavirus SARS-CoV-2 with the company’s automated, high-throughput cobas 6800/8800 platforms. Roche also supplies other SARS-CoV-2 test solutions that are made available for lower volume testing on the MagNA Pure and LightCycler systems (Research Use Only) and the company continues to work on expanding its portfolio of COVID-19 test solutions.